Michael Krsulich
Head of Quality AssuranceMr. Michael Krsulich is Head of Quality Assurance of TuHURA Biosciences, Inc. from November 2024. Mr. Krsulich has established diverse international expertise supporting progression of therapies from clinical development through commercialization and leading GxP Quality oversight. Mr. Krsulich joins TuHURA having most recently served as Vice President, Global Quality Assurance (CRO) at Reaction Biology Corporation, designed and implemented a global quality management strategy for all sites across the US and EU and implemented a global quality management system and risk management program. Mr. Krsulich served as Senior Director, GxP Quality Assurance (Gene Therapy) at Renovacor, Inc. (acquired by Rocket Pharmaceuticals). His experience include Senior Director, Quality Assurance GMP (small molecule) at Galera Therapeutics, Inc.; Associate Director, R&D Quality Assurance (small /large molecule, biosimilars) at Teva Pharmaceuticals Industries, where he led the GMP QA activities for Teva's first commercially approved biologic (AJOVY fremanezumab-vfrm); Senior Manager, Development Quality Assurance (small/large molecule, ADC) at Eisai, Inc.; Quality Site Lead (large molecule) at OPK Biotech, LLC.; and Quality Assurance Specialist Team Leader (medical device, biomaterials) at Global Medical, Inc. Mr. Krsulich holds a Bachelor of Science in Psychology from the University of Pittsburgh. He is also a member of the American Society for Quality.
Positions
- Company NameTuHURA Biosciences, Inc.Stock CodeHURAPositionHead of Quality Assurance
